Effect of different durations of ketoconazole dosing on the single-dose pharmacokinetics of midazolam: shortening the paradigm. 2009

S A Stoch, and E Friedman, and A Maes, and K Yee, and Y Xu, and P Larson, and M Fitzgerald, and J Chodakewitz, and J A Wagner
Merck & Co, Inc, Whitehouse Station, NJ, USA. aubrey_stoch@merck.com

Given the prominent role of cytochrome P450 3A (CYP3A) in the metabolism of drugs, it is critical to determine whether new chemical entities will be affected by the inhibition of this enzyme system and result in clinically relevant drug interactions. Ketoconazole interaction studies are frequently performed to determine a given compound's sensitivity to CYP3A metabolism. The present study evaluated whether probing a sensitive substrate (midazolam) with a potent inhibitor (ketoconazole) at earlier time points (days 1 or 2) might be used to reliably gauge the magnitude of a meaningful interaction. The geometric mean ratios (ketoconazole+midazolamday 5/ketoconazole+midazolamday 1 and ketoconazole+midazolamday 5/ketoconazole+midazolamday 2) for midazolam AUC0-infinity were 1.36 and 1.06 with corresponding 90% confidence intervals of (1.17, 1.57) and (0.83, 1.23), respectively. These findings suggest that short-term drug-drug interaction studies can predict the magnitude of change in AUC as reliably as studies using longer duration treatments.

UI MeSH Term Description Entries
D007654 Ketoconazole Broad spectrum antifungal agent used for long periods at high doses, especially in immunosuppressed patients. Nizoral,R-41400,R41,400,R41400,R 41400
D008297 Male Males
D008874 Midazolam A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH. Dormicum,Midazolam Hydrochloride,Midazolam Maleate,Ro 21-3981,Versed,Hydrochloride, Midazolam,Maleate, Midazolam,Ro 21 3981,Ro 213981
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008962 Models, Theoretical Theoretical representations that simulate the behavior or activity of systems, processes, or phenomena. They include the use of mathematical equations, computers, and other electronic equipment. Experimental Model,Experimental Models,Mathematical Model,Model, Experimental,Models (Theoretical),Models, Experimental,Models, Theoretic,Theoretical Study,Mathematical Models,Model (Theoretical),Model, Mathematical,Model, Theoretical,Models, Mathematical,Studies, Theoretical,Study, Theoretical,Theoretical Model,Theoretical Models,Theoretical Studies
D003198 Computer Simulation Computer-based representation of physical systems and phenomena such as chemical processes. Computational Modeling,Computational Modelling,Computer Models,In silico Modeling,In silico Models,In silico Simulation,Models, Computer,Computerized Models,Computer Model,Computer Simulations,Computerized Model,In silico Model,Model, Computer,Model, Computerized,Model, In silico,Modeling, Computational,Modeling, In silico,Modelling, Computational,Simulation, Computer,Simulation, In silico,Simulations, Computer
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

S A Stoch, and E Friedman, and A Maes, and K Yee, and Y Xu, and P Larson, and M Fitzgerald, and J Chodakewitz, and J A Wagner
January 2002, Drug metabolism and disposition: the biological fate of chemicals,
S A Stoch, and E Friedman, and A Maes, and K Yee, and Y Xu, and P Larson, and M Fitzgerald, and J Chodakewitz, and J A Wagner
February 2001, Pharmacotherapy,
S A Stoch, and E Friedman, and A Maes, and K Yee, and Y Xu, and P Larson, and M Fitzgerald, and J Chodakewitz, and J A Wagner
May 2012, Cancer chemotherapy and pharmacology,
S A Stoch, and E Friedman, and A Maes, and K Yee, and Y Xu, and P Larson, and M Fitzgerald, and J Chodakewitz, and J A Wagner
November 1986, Research communications in chemical pathology and pharmacology,
S A Stoch, and E Friedman, and A Maes, and K Yee, and Y Xu, and P Larson, and M Fitzgerald, and J Chodakewitz, and J A Wagner
November 2012, Xenobiotica; the fate of foreign compounds in biological systems,
S A Stoch, and E Friedman, and A Maes, and K Yee, and Y Xu, and P Larson, and M Fitzgerald, and J Chodakewitz, and J A Wagner
May 2013, Journal of clinical pharmacology,
S A Stoch, and E Friedman, and A Maes, and K Yee, and Y Xu, and P Larson, and M Fitzgerald, and J Chodakewitz, and J A Wagner
February 2010, Journal of veterinary pharmacology and therapeutics,
S A Stoch, and E Friedman, and A Maes, and K Yee, and Y Xu, and P Larson, and M Fitzgerald, and J Chodakewitz, and J A Wagner
January 1985, European journal of clinical pharmacology,
S A Stoch, and E Friedman, and A Maes, and K Yee, and Y Xu, and P Larson, and M Fitzgerald, and J Chodakewitz, and J A Wagner
July 2006, Cancer biology & therapy,
S A Stoch, and E Friedman, and A Maes, and K Yee, and Y Xu, and P Larson, and M Fitzgerald, and J Chodakewitz, and J A Wagner
December 2015, European journal of clinical pharmacology,
Copied contents to your clipboard!